We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Research Collaborations and Additional Grant for Immunotherapy TABs
News

New Research Collaborations and Additional Grant for Immunotherapy TABs

New Research Collaborations and Additional Grant for Immunotherapy TABs
News

New Research Collaborations and Additional Grant for Immunotherapy TABs

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Research Collaborations and Additional Grant for Immunotherapy TABs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Medigene AG has announced that its subsidiary Trianta Immunotherapies GmbH entered two new research collaborations for further development of its immunotherapy platform TABs (T-cell-specific AntiBodies) for the treatment of various types of cancer and autoimmune diseases.

In the future, scientists of the Max Delbrück Center for Molecular Medicine (MDC) and the Helmholtz Zentrum München - German Research Center for Environmental Health, Munich (HMGU) will undertake single research and development tasks in this special field.

Preclinical in vivo data about the treatment of autoimmune diseases and T cell leukemia with monoclonal antibodies generated during the granted period will be of great value for further clinical development of this immunotherapy platform.

Overall, the collaboration with both research institutions offers Medigene extended scientific synergies regarding technology transfer, infrastructure and exchange of knowledge.

Additionally, Trianta will receive increased public funding for its immunotherapy platform TABs. The grant which has already been awarded by the Federal Ministry of Education and Research, (Bundesministerium für Bildung und Forschung = BMBF) within the scope of the "m4 - Personalized Medicine and Targeted Therapies: a new Dimension of Drug Development" Munich Leading-Edge Cluster initiative in beginning of June, now has been increased.

The sponsored project intends to provide evidence of the elimination of pathogenic T cells in T-cell leukemia and autoimmune diseases, applying in-vivo and in-vitro methods with T-cell receptor-specific monoclonal antibodies. The project is financed by Medigene (60%) as well as the BMBF grant (40%).

Advertisement